Protriptyline in obstructive sleep apnea: a double-blind trial.

Area of Science:

• Sleep Medicine
• Pharmacology
• Pulmonology

Background:

• Obstructive sleep apnea (OSA) is a common sleep disorder characterized by repeated airway collapse.
• Current treatments for OSA may have limitations or side effects.
• Nonsedating medications are being explored as alternative or adjunctive therapies.

Purpose of the Study:

• To evaluate the efficacy of protriptyline, a tricyclic antidepressant, in treating obstructive sleep apnea.
• To assess the impact of protriptyline on daytime somnolence, nocturnal oxygenation, and sleep architecture in OSA patients.

Main Methods:

• A double-blind, crossover study design was employed.
• Five male participants with obstructive sleep apnea were enrolled.
• Treatment duration included two weeks and six months of protriptyline administration.

Main Results:

• Protriptyline significantly reduced daytime somnolence and improved nocturnal oxygenation within two weeks.
• A marked reduction in Rapid-Eye-Movement (REM) sleep and REM-related apnea events was observed.
• After six months, further improvements included decreased body weight, apnea frequency, and arousal frequency.

Conclusions:

• Protriptyline demonstrates efficacy in reducing symptoms of obstructive sleep apnea, particularly in non-life-threatening cases.
• The drug's ability to reduce REM sleep appears to be a key mechanism for improving sleep apnea.
• Protriptyline offers a potential therapeutic option for managing obstructive sleep apnea, improving sleep quality and daytime function.